OnabotA use on the rise for NGB: Proportion of augmentation procedures, incontinent diversions see decrease over study period.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      The article reports on research which found a dramatic decline in the rates of bladder augmentation and incontinent diversions, corresponding to an increasing use of onabotulinum toxin A (onabotA) for patients with neurogenic bladder (NGB). Topics discussed include implications of the changes in the rate of onabotA use on the management of patients with neurogenic bladder.